Navigation Links
deCODE genetics Announces Third Quarter 2008 Financial Results

REYKJAVIK, November 6 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter ended September 30, 2008. A conference call to discuss the quarter's results, recent operating highlights and a strategic update will be webcast live tomorrow, Friday, November 7, at 8:00am EST/1pm GMT (details below).

Operating loss for the third quarter 2008 was $11.3 million, compared to $22.2 million for the third quarter 2007. Operating loss for the first nine months of 2008 declined to $44.4 million from $65.7 million for the first nine months of 2007.

Net loss for the quarter ending September 30, 2008 was $17.9 million, compared to $24.2 million for the third quarter 2007. Net loss for the first nine months of 2008 was $62.9 million, compared to $63.1 million for the first nine months of last year. In addition to operating loss, net loss figures for the periods presented include interest expense and, in the 2008 periods, unrealized loss resulting from the revaluation of the company's auction rate securities investments. The nine-month figure for 2007 also includes a one-time payment deCODE received related to the settlement of an intellectual property suit.

Basic and diluted net loss per share was $0.29 for the third quarter 2008, compared to $0.40 for the same quarter in 2007. For the first nine months of 2008, basic and diluted net loss per share was $1.03, unchanged from that for the first nine months of last year. At the close of the third quarter 2008, the company had approximately 61.8 million shares outstanding.

Revenue for the third quarter this year was $12.0 million, compared to $10.9 million for the same period a year ago. For the first nine months of 2008, revenue was $42.0 million, compared to $27.1 million for the same period last year. As of September 30, 2008, the company had $17.7 million in deferred revenue that will be recognized over future reporting periods. The period-on-period increase in revenue for the third quarter and first nine months of 2008 was driven principally by growth in the company's genomic services business, which includes the company's diagnostics, deCODEme(TM) personal genome analysis, and contract genotyping businesses.

Research and development expense was $5.7 million for the third quarter of this year, compared to $14.1 million for the same period last year. For the first nine months of 2008, R&D expense was $26.3 million, compared to $41.3 million for the first nine months of 2007. Our research and development expense in the first nine months of this year reflects the conclusion of clinical pharmacology studies in our most advanced drug development programs, preparations for the IND filing for our PDE4 modulator DG071, the launch of our prostate cancer, glaucoma and breast cancer tests, and the advancement of gene and target discovery work in a range of major disease areas.

Selling, general and administrative expense for the third quarter of 2008 was $6.7 million, compared to $7.1 million for the 2007 period. For the first nine months of the year, SG&A expense was $21.0 million in 2008 and $19.4 million in 2007.

At September 30, 2008, the company had liquid funds available for operating activities (cash and cash equivalents together with current investments) of $11.8 million, as compared to $23.7 million at June 30, 2008 and $64.2 million at December 31, 2007. The net utilization of liquid funds in the three and nine-month periods ended September 30, 2008 was $12.0 million and $52.4 million, respectively. At September 30, 2008, the company had $35.5 million in cash, cash equivalents and investments, comprised of the $11.8 million in cash and cash equivalents, as well as $5.5 million in restricted investments in U.S. Treasury Bills and $18.2 million in illiquid, non-current investments in auction rate securities. At December 31, 2007, the company had $94.1 million in cash, cash equivalents, restricted cash equivalents, and investments.

The company is undertaking a review of its long-term business strategy with the goal of sharpening the focus of its business, selling assets, securing partnerships, and utilizing the resources generated to support product development and marketing efforts in its core business. The company has utilized a 30-day grace period for the scheduled October 15 interest payment on its 3.5% Senior Convertible Notes due 2011 and is reviewing methods for making this payment. Given its current liquid assets, and without paying the interest on its Notes from its present funds, the company must obtain further financial resources through either the implementation of strategic alternatives, corporate partnerships, or the sale of or loans secured by its auction rate securities in order to continue operations beyond the end of this year. The company is focused on reducing expenses and speeding the evaluation of its strategic options in order to obtain the resources to do so.

deCODE has significant operations in Iceland and pays a large proportion of its fixed costs in Icelandic krona, while its sales are generally denominated in US dollars and its reporting currency is the US dollar. During the third quarter and beginning of the fourth quarter the global financial crisis caused significant economic turmoil in Iceland. As a result, the value of the Icelandic krona has declined significantly versus the US dollar. The turmoil in the Icelandic financial sector and economy as a whole have not to date had any significant adverse impact on deCODE or its day to day operations. deCODE is monitoring closely the situation in Iceland, the principal impact of which for the company has been to decrease the dollar value of our krona-denominated costs. deCODE's most significant operating expenses denominated in krona include salaries and rental payments on our leased facilities and capital equipment. In as far as the krona decreases in value versus the U.S. dollar that portion of our overall operating expenses that are payable in krona will decrease.

"Over the past few months we have continued to bring forward new products for treating and preventing common diseases. Utilizing the expertise of our protein crystallography and medicinal chemistry units we have filed an IND on an exciting new PDE4 modulator for Alzheimer's disease that has the potential to avoid some of the side effects of earlier compounds. We have also just launched the first DNA-based test for risk of the common forms of breast cancer, a test which promises to improve the way in which we target intensive screening and thus to catch more cancers earlier. At the same, in a global economic climate in which there is limited access to capital for companies of our size, we believe that the best way to develop and capture the value of our capabilities and product portfolio is to sharpen the focus of our business. We are therefore in the process of reviewing our long-term strategy and will be sharing with you the results of this process in the weeks ahead," said Kari Stefansson, CEO of deCODE.

Recent highlights include:

Product Development

- DG071 for Alzheimer's and cognition deficits. In October 2008 we filed

an investigational new drug (IND) application for DG071, a novel small-

molecule modulator of phosphodiesterase 4 (PDE4), being developed for

Alzheimer's and other cognitive disorders. The compound is being

developed as a new and potentially safer means of targeting PDE4 to

combat memory loss and cognitive deficits associated with Alzheimer's

disease and other disorders in which neural signaling is reduced or

impaired. First and second generation PDE4 inhibitors such as rolipram,

cilomilast, and roflumilast caused significant side effects, including

nausea and vomiting, at therapeutic doses in human clinical trials.

Data generated at deCODE suggest that the observed side effects were

closely correlated with the binding of these molecules in the PDE4

enzymatic active site competitively with cAMP. As cAMP is of critical

importance to neuronal signaling, the goal of deCODE's program has been

to discover compounds that would modulate PDE4 activity via an

allosteric mechanism to improve safety and tolerability. Towards this

goal, the decode biostructures team solved multiple novel co-crystal

structures of PDE4D & PDE4B containing regulatory domains with bound

ligands. Those structures allowed the deCODE chemistry team to identify

a novel binding site for allosteric modulators in the PDE4 regulatory

domain. In animal models, DG071 has been shown to significantly improve

learning and long- and short-term memory at doses that offer a wide

margin for safety and tolerability.

- deCODE Breast Cancer. In October, deCODE launched deCODE

BreastCancer(TM), the company's latest DNA-based disease risk test, for

assessing individual risk of the common forms of breast cancer and

personalizing screening and treatment strategies. The seven markers

measured by the test, discovered by deCODE and others, contribute to

the incidence of an estimated 60 percent of all breast cancers. The

test integrates data from discovery and replication studies published

in major peer-reviewed journals and involving nearly 100,000 breast

cancer patients and healthy volunteers from many populations. The test

can identify the roughly 5 percent of women who are at a greater than

20 percent lifetime risk of the common forms of breast cancer (about

twice the average risk in the general population), and the 1 percent of

women whose lifetime risk is roughly 36 percent (about three-times

average). According to American Cancer Society guidelines, women with a

lifetime risk of 20 percent or greater should receive annual MRI breast

screenings in additional to mammograms, and women at 15 to 20 percent

lifetime risk should talk with their doctors about the benefits and

limitations of adding MRI screening to their yearly mammogram.

Target Discovery

- Bladder cancer. deCODE and colleagues in the Netherlands discovered two

common single-letter variants in the human genome (SNPs) that confer

increased risk of urinary bladder cancer. Approximately 20% of people

of European descent carry two copies of the first variant, a version of

a SNP on chromosome 8q24, putting them at a 50% higher risk of

developing bladder cancer than those without the variant. Individuals

who carry two copies of a common version of another SNP on chromosome 3

were found to be at a 40% higher risk of the disease than non-carriers.

These are the best-replicated genetic variants ever linked to bladder

cancer risk, and the study analysed genotypic data from more than

40,000 patients and controls from Iceland, the Netherlands and eight

other European countries. These findings were folded into deCODEme and

may be combined with other risk variants to develop a disease-risk

diagnostic test.

- Skin cancer. deCODE discovered common versions of two single-letter

variations in the human genome (SNPs) that confer risk of basal cell

carcinoma (BCC), the most common cancer among people of European

ancestry. Unlike the four sets of SNPs previously found by deCODE to

confer risk of BCC and cutaneous melanoma, these new variants are not

linked to fair pigmentation traits that also make certain people prone

to freckling and sunburn. These SNPs, both located on chromosome 1, may

therefore provide new insight into an underlying biological mechanism

causing BCC, independent of the impact of exposure to ultraviolet (UV)

radiation in sunlight. Approximately 2% of people of European descent

carry two copies of the risk versions of both SNPs, and are at a 170%

greater risk of BCC than those who do not carry the risk variants.

These SNPs were immediately incorporated into deCODEme(TM).

Corporate Development and Finance

- Strategic Review. Last month, deCODE announced that it is conducting a

review of its long-term business strategy. deCODE has utilized its

capabilities in medicinal chemistry, structural biology and human

genetics to develop product and intellectual property portfolios in

both therapeutics and DNA-based diagnostics. The goal of this strategic

review is to optimize the value of these assets for its shareholders by

sharpening the focus of its business, selling non-core assets, securing

strategic partnerships, and utilizing the resources generated to

underpin product development and marketing efforts in its core

business. The company has engaged the Stanford Group Company to assist

in evaluating strategic alternatives and in executing swiftly on the

results of this review through the identification of buyers and

partners for non-core business units, programs and intellectual

property. deCODE plans to provide an update on this process in

tomorrow's conference call. In order to provide more time for the

completion of this review and the execution of alternatives including

the sale of assets, deCODE announced that it had elected to utilize a

30-day grace period for the scheduled October 15 interest payment on

its outstanding 3.5% Senior Convertible Notes due 2011. Failure to pay

the interest within 30 days of the due date will constitute an event of

default. If an event of default occurs and is continuing, the trustee

or the holders of at least 25% in aggregate principal amount of the

notes then outstanding may declare the notes due and payable at their

principal amount together with accrued interest.

- Nasdaq Notification. deCODE has requested a hearing before a Nasdaq

Listing Qualifications Panel to present a plan for regaining compliance

with Nasdaq Marketplace Rule 4450(b)(1)(A), which requires a minimum

market value of listed securities of $50 million. On October 31, 2008,

deCODE received a Staff Determination Letter from The Nasdaq Stock

Market LLC indicating that the Company had not regained compliance with

this rule during the time period provided by Nasdaq in a previous

notice as disclosed in the Company's press release dated October 6,

2008, and therefore its Common Stock is subject to delisting from The

Nasdaq Global Market at the opening of business on November 11.

Following the hearing request, the Company's common stock will continue

to be listed on The Nasdaq Global Market pending the conclusion of the

hearing process and during any extension period which may be granted by

the Panel. It is expected that the hearing would be held within 45

days. The Panel has discretion to grant an extension not to exceed 180

days from the date of the Staff notification for the Company to regain

compliance with applicable listing standards. There can be no assurance

that the Panel will grant the Company's request for continued listing.

About deCODE

deCODE is a bio-pharmaceutical company developing drugs and DNA-based tests to improve the treatment, diagnosis and prevention of common diseases. Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer's disease and other conditions. deCODE is a global leader in human genetics, and has identified key variations in the genome (SNPs) conferring increased risk of major public health challenges from cardiovascular disease to cancer. Based upon these discoveries deCODE has brought to market a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases. Through its CLIA-registered laboratory, deCODE is offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer, for the common forms of breast cancer. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at; on our diagnostics site at; for our pioneering personal genome analysis service, integrating the genetic variants included in these tests and those linked to another twenty common diseases, at; and on our blog at

Conference Call Information

A conference call, during which deCODE President and CEO Kari Stefansson and CFO Lance Thibault will discuss third quarter financial results and recent operating highlights, will be webcast tomorrow, Friday, November 7, at 8:00am US Eastern Standard Time/1pm GMT. The webcast can be accessed via the Investors section of deCODE's website,, or through A replay of the call will be available on these websites for at least one week following the call. A digitized telephone replay of the call can be accessed for the week following the call by dialing 1-800-475-6701 from the US, or +1-320-365-3844 from outside the US. The access code is 967723.

Condensed Consolidated Statements of Operations

For the three months For the nine months

ended September 30, ended September 30,

2008 2007 2008 2007

in thousands, except per share amounts (unaudited)

Revenue $ 11,978 $ 10,892 $ 41,982 $ 27,060

Operating expenses

Cost of revenue 10,992 11,976 39,138 32,050

Research and development 5,652 14,069 26,269 41,273

Selling, general and

administrative 6,661 7,070 21,018 19,395

Total operating expense 23,305 33,115 86,425 92,718

Operating loss (11,327) (22,223) (44,443) (65,658)

Interest income 500 1,646 1,989 5,155

Interest expense (4,187) (4,019) (12,332) (11,488)

Other non-operating

income and

(expense), net* (2,886) 348 (8,133) 8,890

Net loss $ (17,900) $ (24,248) $ (62,919) $ (63,101)

Basic and diluted

net loss per share: $ (0.29) $ (0.40) $ (1.03) $ (1.03)

Shares used in

computing basic and

diluted net

loss per share 61,418 61,033 61,353 60,996

Condensed Consolidated Balance Sheet Data

At At

September 30, December 31,

2008 2007

in thousands (unaudited)

Cash and investments ** $ 35,487 $ 94,058


assets 100,244 156,208


liabilities 304,033 301,858

Total shareholders'

equity (203,789) (145,650)

* Other non-operating expense for the three and nine months ended September 30, 2008 principally reflect an unrealized loss resulting from the revaluation of the company's non-current auction rate security investments as of September 30, 2008.

** Cash and investments include cash equivalents, restricted investments and cash equivalents, and non-current investments.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effect of a potential delisting of our common stock from The Nasdaq Global Market, uncertainty regarding potential future deterioration in the market for auction rate securities which could negatively affect our cash position and result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


deCODE genetics:

Joy Bessenger,

+1-212-481-3891, ;

Edward Farmer,

+354-570-2819, ;

Gisli Arnason,

+354-570-1900, .

SOURCE deCODE genetics Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. deCODE genetics Announces Third Quarter 2007 Financial Results
4. deCODE Launches deCODEme(TM)
5. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
6. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
7. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
8. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
9. deCODE Genetics Announces Full-year 2007 Financial Results
10. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference
11. deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference
Post Your Comments:
(Date:10/10/2017)... ... , ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled ... bold new look is part of a transformation to increase awareness, appeal to new ... , It will also expand its service offering from its signature gourmet cooking classes ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
(Date:10/9/2017)... , ... October 09, 2017 , ... At its national ... Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been ... a member of the winning team for the 2015 Breakthrough Prize in Fundamental physics ...
(Date:10/7/2017)... WALTHAM, Mass. , Oct. 6, 2017 /PRNewswire/ ... pioneering work of three scientists, Jacques Dubochet, ... whose breakthrough developments in cryo-electron microscopy ... this technology within the structural biology community. The ... Scientific. Scientists can now routinely produce highly resolved, ...
Breaking Biology Technology:
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):